Human igm antibodies with the capability of inducing remyelination, and diagnostic and therapeutic uses thereof particularly in the central nervous system
CA 2901451 C · Owner: Mayo Foundation For Medical Education & Research · Inventors: Pease, Larry R.; Rodriguez, Moses; Miller, David J.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Methods are described for treating demyelinating diseases in mammals such as multiple sclerosis in humans, and viral diseases of the central nervous system of humans and domestic animals such as post-infections encephalomyelitis or prophylactically inhibiting the initiation or progression of demyelination in these disease states using human monoclonal autoantibodies characterized by their ability to bind structures and cells within the central nervous system. In particular the methods utilize human monoclonal antibodies selected from the group of sHIgM22 (LIM 22) sHIgM46 ebvHlgM MSI19D10, CB2bG8, AKJR4 CB2iE12,C B2iE7 and MSI 19E5, monomers thereof active fragments thereof and isolated or …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed May 30, 2000 and granted April 7, 2020. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended May 30, 2020.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by May 30, 2022.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.